Scholarlink

<p>The RNA pseudoknot of SARS-CoV-2 plays a pivotal role in − 1 programmed ribosomal frameshifting (− 1 PRF), which is essential for viral protein synthesis and replication. Targeting this RNA structural element offers a novel therapeutic strategy against COVID-19. In this study, we applied an integrative computational approach combining molecular docking, MM-GBSA binding free energy calculations, ADME–Tox profiling, and extended 500&#xa0;ns molecular dynamics simulations to identify small molecules capable of disrupting the pseudoknot function. F2879–5340 emerged as a promising RNA-targeting candidate, demonstrating stable interactions with key pseudoknot nucleotides and favorable ΔG_bind values. Compared to the control compound Nafamostat, F2879–5340 exhibited superior predicted pharmacokinetic properties, including higher intestinal absorption, better bioavailability, and no mutagenic potential. These results suggest that F2879–5340 is a potent candidate for further experimental validation as an orally bioavailable − 1 PRF inhibitor. This work presents a novel computational pipeline for RNA-targeted drug discovery in the context of SARS-CoV-2.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting viral RNA pseudoknots: a multi-level computational approach to identify RNA-binding novel small molecules

  • 期刊论文

  • 发表日期：

    2025年9月26日

查看全文
  • Neha Jeena,
  • Sahal Bin Saleem CP,
  • Shubham Srivastava,
  • Devesh M. Sawant,
  • Inshad Ali Khan

摘要

The RNA pseudoknot of SARS-CoV-2 plays a pivotal role in − 1 programmed ribosomal frameshifting (− 1 PRF), which is essential for viral protein synthesis and replication. Targeting this RNA structural element offers a novel therapeutic strategy against COVID-19. In this study, we applied an integrative computational approach combining molecular docking, MM-GBSA binding free energy calculations, ADME–Tox profiling, and extended 500 ns molecular dynamics simulations to identify small molecules capable of disrupting the pseudoknot function. F2879–5340 emerged as a promising RNA-targeting candidate, demonstrating stable interactions with key pseudoknot nucleotides and favorable ΔG_bind values. Compared to the control compound Nafamostat, F2879–5340 exhibited superior predicted pharmacokinetic properties, including higher intestinal absorption, better bioavailability, and no mutagenic potential. These results suggest that F2879–5340 is a potent candidate for further experimental validation as an orally bioavailable − 1 PRF inhibitor. This work presents a novel computational pipeline for RNA-targeted drug discovery in the context of SARS-CoV-2.